Canadian Journal of Public Health

, Volume 101, Issue 1, pp 12–14 | Cite as

Meningococcal Serogroup C Conjugate Vaccination in Canada: How Far Have We Progressed? How Far Do We Have to Go?

  • Craig P. White
  • Jeff ScottEmail author


Since routine meningococcal C conjugate vaccination was introduced into Canada in 2002, there have been a large regional variation in the routine programs, changes to the timing of the infant series in some provinces, and wide differences in catch-up programs. As immunization is viewed as a provincial responsibility, less attention has been paid to determining national coverage rates and the direct and indirect effects of the widely varying provincial/territorial vaccination programs on the nation as a whole. Canada’s disjointed regional immunization campaigns leave the population at risk of disease for an extended length of time. The United Kingdom has proven that with a pro-active approach to planning, coordination, and implementation of a national immunization program, excellent long-term control of invasive meningococcal disease in a large population could be achieved in as little as one year. A summation of the current meningococcal immunization strategies used in Canada and an estimate of overall vaccine coverage of children and youth is provided.


Immunization meningococcal C conjugate vaccine coverage rate herd immunity Canada 


Depuis le lancement de l’immunisation systématique contre le méningocoque du groupe C par le vaccin conjugué au Canada en 2002, on observe d’importants écarts régionaux dans les programmes de vaccination systématique, des changements dans le calendrier vaccinal des nourrissons de certaines provinces et de grandes différences dans les programmes de rattrapage. L’immunisation étant de compétence provinciale, on a peu cherché à déterminer les taux de couverture nationaux et les effets directs et indirects des importants écarts dans les programmes de vaccination des provinces et des territoires sur l’ensemble du pays. Les campagnes de vaccination régionales disjointes du Canada exposent la population à la maladie sur une période prolongée. Au Royaume-Uni, on a prouvé qu’en abordant de façon proactive la planification, la coordination et la mise en œuvre d’un programme national d’immunisation, on peut obtenir en une seule année un excellent contrôle à long terme des méningococcies invasives dans une vaste population. Nous présentons une synthèse des stratégies d’immunisation contre le méningocoque en usage au Canada et une estimation de la couverture vaccinale globale des enfants et des adolescents.


immunisation vaccin conjugué contre le méningocoque du groupe C taux de couverture immunité de groupe Canada 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    National Advisory Committee on Immunization (NACI). Enhanced Surveillance of Invasive Meningococcal Disease in Canada: 1 January, 2004, through 31 December, 2005. Can Commun Dis Rep 2007;33(10):1–15.Google Scholar
  2. 2.
    National Advisory Committee on Immunization (NACI). Update on the Invasive Meningococcal Disease and Meningococcal Vaccine Conjugate Recommendations. Can Commun Dis Rep 2009;36(ACS3):1-40.Google Scholar
  3. 3.
    Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: Database analysis. BMJ 2003;326(7385):365–66.CrossRefGoogle Scholar
  4. 4.
    Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: A success story. Vaccine 2001;20(Suppl 1):S58–S67.CrossRefGoogle Scholar
  5. 5.
    DeWals P, Deceuninck G, Boulianne N, DeSerres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 2004;292(20):2491–94.CrossRefGoogle Scholar
  6. 6.
    Bettinger J, Scheifele D, LeSaux M, Halperin S, Vaudry W, Tsang R. The influence of meningococcal serogroup C conjugate vaccine in Canada. Pediatr Infect Dis J 2008;28(3):220–24.CrossRefGoogle Scholar
  7. 7.
    Siu T, Wrency T, Dawar M, Patrick D. The impact of routine immunization using meningococcal C conjugate vaccine on invasive meningococcal disease in British Columbia. Can J Public Health 2008;99(5):380–82.PubMedGoogle Scholar
  8. 8.
    Kinlin LM, Jamieson F, Brown E, Brown S, Rawte P, Dolman S, et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000–2006. Vaccine 2009;27:1735–40.CrossRefGoogle Scholar
  9. 9.
    Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007;31(1):3–14.CrossRefGoogle Scholar
  10. 10.
    British Columbia Centre for Disease Control. Two-year olds; grade six students; grade 12 students with up-to-date immunizations. Vancouver, BC: British Columbia Centre for Disease Control, 2008. Available at: (Accessed September 2008).Google Scholar
  11. 11.
    Statistics Canada. Age and sex, 2006 counts for both sexes, for Canada, provinces and territories - 100% data. Ottawa, ON: Statistics Canada, 2007.Google Scholar
  12. 12.
    Keelan J, Lazar H, Wilson K. The national immunization strategy: A model for resolving jurisdictional disputes in public health. Can J Public Health 2008;99(5):376–79.PubMedGoogle Scholar
  13. 13.
    Borrow R, Miller E. Long-term protection in children with meningococcal C conjugate vaccination: Lessons learned. Expert Rev Vaccines 2006;5(6):851–57.CrossRefGoogle Scholar
  14. 14.
    DeWals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, Nguyen V. Vaccinating adolescents against meningococcal disease in Canada: A cost-effectiveness analysis. Vaccine 2007;25(29):5433–40.CrossRefGoogle Scholar
  15. 15.
    Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 2005;162:89–100.CrossRefGoogle Scholar

Copyright information

© The Canadian Public Health Association 2010

Authors and Affiliations

  1. 1.Canadian Center for VaccinologyIWK Health Centre and Dalhousie UniversityHalifaxCanada

Personalised recommendations